ALPACA: A Reinforcement Learning Environment for Medication Repurposing and Treatment Optimization in Alzheimer’s Disease

Nolan Brady, Tom Yeh
Proceedings of the 7th Conference on Health, Inference, and Learning, PMLR 333:329-353, 2026.

Abstract

Evaluating personalized, sequential treatment strategies for Alzheimer’s disease (AD) using clinical trials is often impractical due to long disease horizons and substantial inter-patient heterogeneity. To address these constraints, we present the Alzheimer’s Learning Platform for Adaptive Care Agents (ALPACA), an open-source, Gym-compatible reinforcement learning (RL) environment for systematically exploring personalized treatment strategies using existing therapies. ALPACA is powered by the Continuous Action-conditioned State Transitions (CAST) model trained on longitudinal trajectories from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), enabling medication-conditioned simulation of disease progression under alternative treatment decisions. We show that CAST autoregressively generates realistic medication-conditioned trajectories and that RL policies trained in ALPACA outperform no-treatment and behavior-cloned clinician baselines on memory-related outcomes. Interpretability analyses further indicated that the learned policies relied on clinically meaningful patient features when selecting actions. Overall, ALPACA provides a reusable in silico testbed for studying individualized sequential treatment decision-making for AD.

Cite this Paper

BibTeX
@InProceedings{pmlr-v333-brady26a, title = {ALPACA: A Reinforcement Learning Environment for Medication Repurposing and Treatment Optimization in Alzheimer’s Disease}, author = {Brady, Nolan and Yeh, Tom}, booktitle = {Proceedings of the 7th Conference on Health, Inference, and Learning}, pages = {329--353}, year = {2026}, editor = {Healey, Elizabeth and Fries, Jason and Pollard, Tom and Tang, Shengpu and Zink, Anna and Hartvigsen, Tom and Agrawal, Monica and Finlayson, Sam and Glicksberg, Benjamin and Beaulieu-Jones, Brett and Wang, Kai and Fontalvo, Daseyra and Sarker, Tasmie and Chen, Irene and Alsentzer, Emily}, volume = {333}, series = {Proceedings of Machine Learning Research}, month = {29--30 Jun}, publisher = {PMLR}, pdf = {https://raw.githubusercontent.com/mlresearch/v333/main/assets/brady26a/brady26a.pdf}, url = {https://proceedings.mlr.press/v333/brady26a.html}, abstract = {Evaluating personalized, sequential treatment strategies for Alzheimer’s disease (AD) using clinical trials is often impractical due to long disease horizons and substantial inter-patient heterogeneity. To address these constraints, we present the Alzheimer’s Learning Platform for Adaptive Care Agents (ALPACA), an open-source, Gym-compatible reinforcement learning (RL) environment for systematically exploring personalized treatment strategies using existing therapies. ALPACA is powered by the Continuous Action-conditioned State Transitions (CAST) model trained on longitudinal trajectories from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), enabling medication-conditioned simulation of disease progression under alternative treatment decisions. We show that CAST autoregressively generates realistic medication-conditioned trajectories and that RL policies trained in ALPACA outperform no-treatment and behavior-cloned clinician baselines on memory-related outcomes. Interpretability analyses further indicated that the learned policies relied on clinically meaningful patient features when selecting actions. Overall, ALPACA provides a reusable in silico testbed for studying individualized sequential treatment decision-making for AD.} }
Endnote
%0 Conference Paper %T ALPACA: A Reinforcement Learning Environment for Medication Repurposing and Treatment Optimization in Alzheimer’s Disease %A Nolan Brady %A Tom Yeh %B Proceedings of the 7th Conference on Health, Inference, and Learning %C Proceedings of Machine Learning Research %D 2026 %E Elizabeth Healey %E Jason Fries %E Tom Pollard %E Shengpu Tang %E Anna Zink %E Tom Hartvigsen %E Monica Agrawal %E Sam Finlayson %E Benjamin Glicksberg %E Brett Beaulieu-Jones %E Kai Wang %E Daseyra Fontalvo %E Tasmie Sarker %E Irene Chen %E Emily Alsentzer %F pmlr-v333-brady26a %I PMLR %P 329--353 %U https://proceedings.mlr.press/v333/brady26a.html %V 333 %X Evaluating personalized, sequential treatment strategies for Alzheimer’s disease (AD) using clinical trials is often impractical due to long disease horizons and substantial inter-patient heterogeneity. To address these constraints, we present the Alzheimer’s Learning Platform for Adaptive Care Agents (ALPACA), an open-source, Gym-compatible reinforcement learning (RL) environment for systematically exploring personalized treatment strategies using existing therapies. ALPACA is powered by the Continuous Action-conditioned State Transitions (CAST) model trained on longitudinal trajectories from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), enabling medication-conditioned simulation of disease progression under alternative treatment decisions. We show that CAST autoregressively generates realistic medication-conditioned trajectories and that RL policies trained in ALPACA outperform no-treatment and behavior-cloned clinician baselines on memory-related outcomes. Interpretability analyses further indicated that the learned policies relied on clinically meaningful patient features when selecting actions. Overall, ALPACA provides a reusable in silico testbed for studying individualized sequential treatment decision-making for AD.
APA
Brady, N. & Yeh, T.. (2026). ALPACA: A Reinforcement Learning Environment for Medication Repurposing and Treatment Optimization in Alzheimer’s Disease. Proceedings of the 7th Conference on Health, Inference, and Learning, in Proceedings of Machine Learning Research 333:329-353 Available from https://proceedings.mlr.press/v333/brady26a.html.

Related Material